Interview with George Varkanis, Managing Director, Celgene
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
Address: Industry House 10 Binara Street CANBERRA ACT 2601
,Australia
Tel: +61 2 6213 6000
Web: http://www.innovation.gov.au/Pages/default.aspx
The Department of Industry, Innovation, Science, Research and Tertiary Education works with our stakeholders to help shape the future economy, through skills, learning, discovery and innovation. Our department, and the wider portfolio, are working to accelerate productivity growth and secure Australia’s prosperity in a competitive global economy.
The Industry, Innovation, Science, Research and Tertiary Education portfolio is accountable to the Australian Parliament through four ministers and two parliamentary secretaries, and comprises the Department of Industry, Innovation, Science, Research and Tertiary Education along with 12 portfolio/prescribed agencies.
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
See our Cookie Privacy Policy Here
